Abstract:OBJECTIVE:To evaluate the safety and validity of neo-adjuvant chemoradiotherapy followed by surgery for locally advanced esophageal carcinoma.METHODS:Patients with IIB, III staged squamous cell carcinoma of thoracic esophagus were randomly allocated to either preoperative chemoradiotherapy followed by surgery (arm A) or surgery alone (arm B). In arm A, chemotherapy and radiotherapy were performed concurrently. Patients received two cycles of vinorelbine and cisplatin. Vinorelbine at 25 mg/m(2) per day was administered as a bolus infusion at d1, d8, d22 and d29. Cisplatin at 75 mg/m(2) was administered by an intravenous infusion at d1 and d22 (or 25 mg/m(2) days 1 - 4 and 22 - 25). A total radiotherapeutic dose of 40 Gy was delivered in 20 daily fractions of 2.0 Gy each (5 d/wk for 4 weeks). Three-incisioned esophagectomy was performed at Weeks 4 - 6 after chemoradiotherapy. Primary outcome was overall survival time. An interim analysis was performed in June 2011.RESULTS:From July 2007 to June 2011, 123 eligible patients were randomly assigned at 7 cooperative cancer centers (54 cases in arm A vs 69 cases in arm B). In arm A, the clinical response rate of chemoradiotherapy was 90.7%. All patients finished the preoperative chemoradiotherapy. Forty-nine cases continued to receive esophagectomy. The pathological complete response rate was 29.6%. The rate of R0 resection in arm A was significant higher than that in arm B(96.0% vs 85.5%, P = 0.015). The most common grade 3/4 toxicity of chemoradiotherapy was leukopenia occurring in 33 cases (61.1%). Vomiting and esophagitis were usually of Grade 1/2. No patient died or abandoned surgery because of chemoradiation toxicity. Between arms A and B, operative duration, blood loss, duration of chest tube drainage and length of postsurgical hospital stay were similar. The incidences of postoperative heart failure (2.0% vs 1.4%, P = 1.000), anastomotic leakage (8.2% vs 11.6%, P = 0.759) and hoarseness (6.1% vs 4.3%, P = 0.691) were not significantly different. The incidence of pulmonary infection in arm A was slightly higher than that in arm B (8.2% vs 1.4%, P = 0.094). No perioperative deaths occurred in either group. There were no significant differences in overall survivals at 1, 2 years between arms A and B (85.6%/75.5% vs 79.1%/66.1%, P = 0.207). The disease-free survivals at 1, 2 years in arm A were slightly higher than in arm B (86.6%/83.2% vs 70.9%/61.8%, P = 0.075).CONCLUSION:Neo-adjuvant chemoradiation followed by surgery may achieve a high clinical response rate and pathologic complete tumor regression rate. It significantly increases the R0 resection rate and down stage the esophageal cancer patients. But its ultimate efficacy awaits further follow-up studies.

Similar survival after endoscopic submucosal dissection and esophagectomy in early esophageal cancer and synchronous or metachronous head and neck cancer

461. SURGICAL TREATMENT OF STAGE IV ESOPHAGEAL CANCER AFTER CCRT IMPROVES SURVIVAL

Long-term Treatment Results and Prognostic Factors of Synchronous and Metachronous Squamous Cell Carcinoma of Head and Neck and Esophagus

The Recurrence Patterns and Post-Recurrence Survivals in Patients with Locally Advanced Esophageal Squamous Cell Carcinoma (escc) Treated with Preoperative Paclitaxel/Cisplatin-Based Chemoradiotherapy.

Concurrent neoadjuvant chemoradiotherapy could improve survival outcomes for patients with esophageal cancer: a meta-analysis based on random clinical trials

Comparison of Clinical Outcomes and Prognosis Between Surgery and Endoscopic Submucosal Dissection in Patients with Synchronous Multifocal Early Gastric Cancer.

Evaluation of the safety and effectiveness of neoadjuvant combined chemoimmunotherapy in the treatment of locally advanced esophageal squamous cell carcinoma: a retrospective single-arm cohort study

Early esophageal cancer or precancerous lesions treated by endoscopic resection: a single-center retrospective study of 368 cases

A Retrospective Study of Different Treatments of Limited-Stage Small-Cell Esophageal Carcinoma and Associated Prognostic Factor Analysis

Improved Prognosis with Induction Chemotherapy in Pathological Complete Responders after Trimodality Treatment for Esophageal Squamous Cell Carcinoma: Hypothesis Generating for Adjuvant Treatment.

The differences of immunologic and TP53 mutant phenotypes between synchronous and metachronous head and neck cancer and esophageal cancer

Long-term Survival of Patients with Locally Advanced Esophageal Squamous Cell Carcinoma Receiving Esophagectomy Following Neoadjuvant Chemotherapy: a Cohort Study

Long-Term Outcomes of Esophageal Squamous Neoplasia with Muscularis Mucosa Involvement after Endoscopic Submucosal Dissection

Peripheral T lymphocyte and immunocyte subset dynamics: markers of neoadjuvant therapy outcomes in esophageal squamous cell carcinoma

Effect on Survival of Postoperative Therapy in Patients with Primary Small Cell Carcinoma of Esophagus (scce): an Analysis of Multicenter Clinical Outcomes.

Clinical Analysis of Endoscopic Submucosal Dissection for the Synchronous Multiple Primary Early Cancers in Esophagus and Stomach: 12 Cases Report

323. LONG-TERM SURVIVAL OUTCOME OF PATIENTS WITH EARLY ESOPHAGEAL CANCER AFTER ESD (ENDOSCOPIC SUBMUCOSAL DISSECTION) AND ESOPHAGECTOMY

Role of chemotherapy after curative esophagectomy in squamous cell carcinoma of the thoracic esophagus: A propensity score‐matched analysis

Extended Right Thoracic Approach Compared with Limited Left Thoracic Approach for Patients with Middle and Lower Esophageal Squamous Cell Carcinoma Three-year Survival of a Prospective, Randomized, Open-label Trial

[A Multi-Centered Randomized Controlled Study of Neo-Adjuvant Chemoradiotherapy Followed by Surgery Versus Surgery Alone for Locally Advanced Squamous Cell Carcinoma of Esophagus: an Interim Analysis].

Experience in Simultaneous Endoscopic Submucosal Dissection Treating Synchronous Multiple Primary Early Esophageal Cancers.